Rhythm Biosciences (ASX:RHY)
ASX announcement history & article coverage
Transparent by design.
Announcments by Rhythm Biosciences (ASX:RHY) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
ColoSTAT Economic Study - Australian Public Health Savings
Independent model estimates ColoSTAT could save public hospitals $72 million annually
Final Director's Interest Notice - Gavin Fox-Smith
FY26 Appendix 4G and Corporate Governance Statement
FY26 Annual Report
Rhythm Biosciences begins commercialisation but reports $5.93m loss and going concern uncertainty
AGM date and closing date for director nominations
Board Changes
Initial ColoSTAT Assessment in UK opens new market access
Rhythm completes first NHS laboratory transfer phase for ColoSTAT
Initial Director's Interest Notice - Carl Stubbings
Initial Director's Interest Notice - Maureen Baker
FY26 Appendix 4E & Audited Financial Report
Rhythm Biosciences reports $5.93m loss, achieves first commercial sales, and advances ColoSTAT® and geneType™ platforms
Appointment of Non-Executive Directors
Notification of cessation of securities - RHY
ColoSTAT Commercial Rollout Update
Bioshares 2026 Presentation
Quarterly Activities Report and Appendix 4C
Rhythm Biosciences strengthens balance sheet and expands ColoSTAT® commercial rollout in Q4 FY26
